Follow the RenovoRx, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, RenovoRx, Inc. has published 37 insider filings. Market capitalisation: €43.5m. The latest transaction was disclosed on 7 April 2026 (Attribution). Among the most active insiders: Agah Ramtin. Every trade is free.
37
Insider Decl.
n/a
Thresholds
€190,707
30 ops.
Buy Volume
n/a
n/a
Sell Volume
59Σ signal
Buys €190,707n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,792 of 29,024 companies
26.4
score / 100
Value
9
Quality
44
FCF yld-25%
Earn yld-26%
EV/EBITDA·
ROE-100%
Gross mgn71%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
26,000 shares@ US$0.8429.1% of flowCommon StockSEC:0001641172-25-003364:0
Canonical exit: 7 Jul 2025 (T+90)
25 of 37 declarations
About RenovoRx, Inc.
RenovoRx, Inc. is a company focused on developing targeted therapies for cancer treatment. It specializes in local drug delivery to enhance treatment efficacy.